Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

age was 600 mg/day), and is more common in the elderly.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.

Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be increased as tolerated. Doses greater than 600 mg/day are not recommended in patients with mild renal impairment (CrCL = 40-59 mL/min). For patients with moderate renal impairment, doses greater than 400 mg/day are not recommended. Gleevec should be used with caution in patients with severe renal impairment.

In the newly diagnosed CML trial, 2% of patients had (NCI Grades 3/4) hemorrhage.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resol
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... addition of Kent Hance , the former chancellor of ... Hance retired as chancellor in July 2014, after raising $1.2 ... announce that Kent Hance , the most successful chancellor ... Kiromic team not only as an investor, but also as ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... Sept. 19, 2014  4WEB Medical announces the formal ... and ankle osteotomy implants on the market today ... annual meeting in Chicago .  The ... a surgeon,s osteotomy needs with 74 size options included in ... offerings of only 15 to 18 implant sizes, which ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the Deutsche Bank 36th Annual ... presentation takes place on Wednesday, May 4, 2011 at 10:40 ... will be webcast and may be accessed on the Company,s ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 ... and chief financial officer at Amylin Pharmaceuticals, will provide a ... through the "Investors" section of Amylin,s corporate website at ...
Cached Medicine Technology:
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... 19, 2014 Boston Scientific Corp. has ... ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go ... Liebhard LLP reports. According to a Motion ... company asserts that claims involving its Solyx pelvic mesh ... Remedies Code, a section of which shields manufacturers ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Pregnant women who ... premature or low birth weight babies, a new study suggests. ... Vancouver, Canada, and found that expectant mothers who lived in ... had a 20 percent lower risk of very preterm birth ... moderate preterm birth (30 to 36 weeks). Babies born ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Melanoma risk found to have genetic determinant 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Do Greener Neighborhoods Produce Healthier Babies? 2
... , SANTA ROSA, Calif., Sept. 21 Osseon ... cement delivery needle) and Osseoflex DR (steerable and curvable bone ... for marketing and clinical use in the European Union. , ... FDA approval in the United States, and allows for the ...
... , PEMBROKE, Bermuda, Sept. 21 ... announced today that Linda,McSmith, AVP, Risk Management for Allied World ... Allied World, at the Ohio Association of,Ambulatory Surgery Centers (OAASC) ... September 24-25, 2009. , Ms. McSmith,s ...
... , , , ... Inc. ("Astellas"), in partnership with the National Science Teachers Association ... science teachers to participate in the 2009 NSTA New Science ... to a range of tools and resources, while providing the ...
... , , PHILADELPHIA and LONDON, Sept. 21 ... that provides a unique combination of competitive intelligence and sales forecast ... of pipeline and marketed drugs . The product will be ... on October 8 and 9, and Bio Europe 2009 in Vienna ...
... N.C. The Defense Advanced Research Projects Agency (DARPA), the ... Duke University $19.5 million for an effort led by the ... a portable, easy-to-use diagnostic device that can reveal who is ... or sneeze. DARPA is interested in such a ...
... research and real world operation of electronic medical ... have developed, tested and are now operating innovative ... evidence-based medical information between clinical sources and public ... new tools developed by the Regenstrief Institute that ...
Cached Medicine News:Health News:Osseon Receives CE Mark 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 3Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 3Health News:Thomson Reuters Launches Thomson Pharma Partnering Forecast 2Health News:DARPA awards Duke $19.5 million to detect viral infection before symptoms appear 2Health News:Fighting disease outbreaks with 2-way health information exchange 2
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Foley Catheters (Latex) 3-Way...
Medicine Products: